MApping the Methylation of repetitive elements to track the Exposome effects on health: the city of Legnano as a LIving lab
MAMELI aims to explore the adaptive role of repetitive elements in response to environmental factors through a multi-level study, ultimately developing predictive algorithms for disease prevention.
Projectdetails
Introduction
The concept of “exposome” encompasses all human disease determinants encountered during the life course. The exposome induces epigenetic modifications (e.g., DNA methylation). Several studies have investigated how repetitive elements (REs) can be switched on in response to environmental stimuli, but have started from the assumption that altered RE methylation is always detrimental to the health of the affected individual.
Hypothesis
MAMELI proposes an alternative hypothesis that some REs are plastic entities that respond physiologically to the environment; consequently, the ability of DNA to adapt to environmental triggers can be monitored.
Study Design
To test this hypothesis, the MAMELI project will enroll 6200 subjects in the city of Legnano (Italy). The study will be conducted in three levels:
-
Discovery Level:
- This first-level will apply third-generation sequencing methylation assessment on 200 subjects at two-time points: T0 (baseline) and T1 (6 months after T0).
- The discovery level will allow the definition of a pool of REs (“differential REs”) whose methylation can change without impacting genome stability.
-
Tuning Level:
- This second level will be conducted on 2700 subjects (200 subjects from the discovery level + 2500 additional subjects).
- It will allow the development of an algorithm (“MAMELI algorithm”) to predict the relationship between exposome and RE methylation status (“RE methylation signature”).
-
Validation Level:
- In the third level, the MAMELI algorithm will be applied to the second set of the study cohort (n=3500) to calculate the difference between the measured RE methylation signature and the values predicted by the algorithm.
- Additionally, to test the reversibility of RE methylation following lifestyle modifications and its preventive potential, an intervention study will be designed and embedded in the cohort.
Conclusion
MAMELI would represent a breakthrough in the understanding of individual susceptibility to environmental pressures, enabling the development of preventive strategies to avoid disease.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.993.251 |
Totale projectbegroting | € 2.993.251 |
Tijdlijn
Startdatum | 1-8-2023 |
Einddatum | 31-7-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITA DEGLI STUDI DI MILANOpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Metastable Epiallele: Role of Epigenetic Variability for the Development of Metabolic and Endocrine DiseasesThis project aims to identify and characterize metastable epialleles in humans to understand their role in metabolic diseases, using advanced technologies on postmortem samples and stem cells. | ERC Consolid... | € 1.997.969 | 2023 | Details |
Endogenous Retroelements As Transcriptional Parasites And Modulators Of Host ImmunityThis project aims to explore how sporadic transcription of endogenous retroelements influences immune system priming and response to stress, potentially redefining their role in host immunity. | ERC Consolid... | € 1.999.415 | 2023 | Details |
Dissecting the cancer epigenome – fundamental lessons from developmental biologyThis project aims to investigate the parallels between cancer epigenetics and early placental development to uncover novel regulatory mechanisms and their implications for disease. | ERC Advanced... | € 2.487.500 | 2024 | Details |
Deciphering the Exposome by Metabolomic Technology in Breast CancerEXPOMET aims to revolutionize understanding of environmental contaminants and their role in breast cancer through innovative mass spectrometry-based exposome assessment and high-throughput monitoring. | ERC Consolid... | € 2.937.489 | 2023 | Details |
Detecting epigenetic biomarkers in the blood for non-invasive precision oncologyDevelop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution. | ERC Starting... | € 1.500.000 | 2022 | Details |
Metastable Epiallele: Role of Epigenetic Variability for the Development of Metabolic and Endocrine Diseases
This project aims to identify and characterize metastable epialleles in humans to understand their role in metabolic diseases, using advanced technologies on postmortem samples and stem cells.
Endogenous Retroelements As Transcriptional Parasites And Modulators Of Host Immunity
This project aims to explore how sporadic transcription of endogenous retroelements influences immune system priming and response to stress, potentially redefining their role in host immunity.
Dissecting the cancer epigenome – fundamental lessons from developmental biology
This project aims to investigate the parallels between cancer epigenetics and early placental development to uncover novel regulatory mechanisms and their implications for disease.
Deciphering the Exposome by Metabolomic Technology in Breast Cancer
EXPOMET aims to revolutionize understanding of environmental contaminants and their role in breast cancer through innovative mass spectrometry-based exposome assessment and high-throughput monitoring.
Detecting epigenetic biomarkers in the blood for non-invasive precision oncology
Develop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Uitbreiding methylatie platformsMLA Dx ontwikkelt een prognostische methode voor vroeg stadium melanomen via LY75 methylatie, ter verbetering van diagnose en behandeling. | Mkb-innovati... | € 20.000 | 2021 | Details |
GeneticYou – Personal GenomicsOmnigen B.V. en Health E-Solutions B.V. ontwikkelen een softwaretool die DNA-variaties analyseert en gezondheidsrisico's voorspelt, gekoppeld aan smart-devices voor persoonlijke gezondheidsmonitoring. | Mkb-innovati... | € 294.196 | 2015 | Details |
Immuuncel Methylatie ProfileringMLA Diagnostics ontwikkelt een prognostische methode voor vroeg stadium melanomen op basis van LY75 methylatieprofiel. | Mkb-innovati... | € 20.000 | 2024 | Details |
Ontwikkeling van innovatieve prognostische melanoomtestDit project ontwikkelt en valideert een innovatieve prognostische melanoomtest gebaseerd op methylatie van het LY75 gen voor bredere klinische toepassing. | Mkb-innovati... | € 165.130 | 2020 | Details |
Uitbreiding methylatie platforms
MLA Dx ontwikkelt een prognostische methode voor vroeg stadium melanomen via LY75 methylatie, ter verbetering van diagnose en behandeling.
GeneticYou – Personal Genomics
Omnigen B.V. en Health E-Solutions B.V. ontwikkelen een softwaretool die DNA-variaties analyseert en gezondheidsrisico's voorspelt, gekoppeld aan smart-devices voor persoonlijke gezondheidsmonitoring.
Immuuncel Methylatie Profilering
MLA Diagnostics ontwikkelt een prognostische methode voor vroeg stadium melanomen op basis van LY75 methylatieprofiel.
Ontwikkeling van innovatieve prognostische melanoomtest
Dit project ontwikkelt en valideert een innovatieve prognostische melanoomtest gebaseerd op methylatie van het LY75 gen voor bredere klinische toepassing.